Last edition
News about "abelacimab"
Novartis Completes Acquisition of Anthos Therapeutics for Up to USD 3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialise abelacimab.
Abelacimab | 04/04/2025 | By Abha
Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Abelacimab | 12/02/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy